Entity coverage
Vistagen Therapeutics, Inc.
VTGN · 2 events mapped
Market Ontology has mapped 2 distinct macro, policy, and market events to VTGN. Each entry below traces the causal channel from the driver to the assumption it moved.
Recent event impacts
Full ledger →- 2026-06-30EventDirect clinical trial failure for primary and secondary endpoints, leading to significant doubt about fasedienol's broad market viability and regulatory approval pathway.
- 2026-06-30EventPotential for fasedienol to be pursued for a subpopulation, requiring further clinical development and regulatory discussions, which could extend timelines and increase costs.
Continuous coverage for VTGN with alerts, structural playbooks, and options routing lives in the platform. Start a trial →